BPC-157 vs TB-500: differences in origin, mechanism and research
BPC-157 vs TB-500 is one of the most common comparisons in peptide research. Both peptides are studied for tissue repair, and both are often mentioned in the same sentence. They are, however, very different molecules. BPC-157 is a 15 amino acid fragment of a gastric protein. TB-500 is a synthetic peptide derived from thymosin beta-4, a protein that regulates the structure of cells. This article compares the two side by side.
BPC-157 vs TB-500
BPC-157 vs TB-500 is one of the most common comparisons in peptide research. Both peptides are studied for tissue repair, and both are often mentioned in the same sentence. They are, however, very different molecules. BPC-157 is a 15 amino acid fragment of a gastric protein. TB-500 is a synthetic peptide derived from thymosin beta-4, a protein that regulates the structure of cells. This article compares the two side by side.
BPC-157 vs TB-500 at a glance
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Fragment of a protein from human gastric juice | Derived from thymosin beta-4, a protein found in almost all cells |
| Length | 15 amino acids | Short active fragment (often Ac-LKKTETQ); some suppliers use the full 43 amino acid thymosin beta-4 |
| Main research focus | Tendons, ligaments, gut lining, blood vessel formation | Cell migration, wound healing, heart and eye tissue, hair follicles |
| Proposed mechanism | Growth factor signalling, nitric oxide system | Binding of actin, a protein that cells use to move |
| Main evidence type | Rodent and cell studies | Rodent and cell studies; some clinical work on full thymosin beta-4 |
| WADA status | Prohibited (S0) | Prohibited (S2) |
What TB-500 is and how it differs from BPC-157
If you already know what BPC-157 is, TB-500 needs a little more explanation. Thymosin beta-4 is a natural protein of 43 amino acids. It is present in almost every cell of the body and is especially concentrated in blood platelets and white blood cells. Its main known job is to bind actin. Actin is a structural protein that cells use to change shape and to move.
TB-500 is a synthetic peptide that is based on the actin-binding region of thymosin beta-4. In the literature this region is often described as the sequence LKKTETQ (amino acids 17 to 23). The name "TB-500" is not a scientific standard, and products sold under this name can differ. Some contain only the short fragment, others the full thymosin beta-4. For research work, it is important to check which sequence a supplier provides.
BPC-157 vs TB-500: proposed mechanisms
The two peptides seem to act on tissue repair from different directions. This is also the reason why researchers often study them together.
BPC-157 mechanism
Studies on BPC-157 describe effects on growth factor receptors such as VEGFR2, on the nitric oxide system and on the outgrowth of fibroblasts. Fibroblasts are the cells that produce new connective tissue. A cell study by Chang et al. (2011) showed increased survival and migration of tendon fibroblasts after BPC-157 treatment.
TB-500 mechanism
Research on thymosin beta-4 focuses on cell migration. By regulating actin, thymosin beta-4 influences how quickly cells can move into damaged tissue. A review by Goldstein et al. (2012) in Expert Opinion on Biological Therapy describes effects on wound closure, new blood vessel formation and the reduction of inflammation in animal models. Philp et al. (2004) reported in The FASEB Journal that thymosin beta-4 activated hair follicle stem cells in mice.
Study quality: BPC-157 vs TB-500
For both compounds, most of the evidence comes from animals and cell cultures. There are still some differences:
BPC-157: A large number of studies exist, but most come from one research group in Zagreb. Independent replication is limited, and controlled human trials are missing.
TB-500: The research on the full protein thymosin beta-4 is broader and comes from several independent groups. Thymosin beta-4 has also been tested in early clinical trials, for example as eye drops and as a wound gel. These results cannot automatically be transferred to the short TB-500 fragment.
In short, neither peptide has proven effects in humans. Thymosin beta-4 has a broader independent research base, while BPC-157 has a larger number of studies from a smaller group of authors.
BPC-157 and TB-500 in combination research
Because the proposed mechanisms are different, many researchers study BPC-157 and TB-500 together. The idea is that one peptide may support growth factor signalling while the other supports cell migration. Published studies that test the combination directly are rare, so this approach is still a hypothesis rather than an established result.
For this kind of research, you can use the individual compounds BPC-157 10 mg and TB-500 10 mg, or the ready-made BPC-157 / TB-500 blend 10/10 mg. A broader blend that also contains GHK-Cu and KPV is available as the BPC-157 / GHK-Cu / TB-500 / KPV blend.
Regulatory status of BPC-157 and TB-500
Neither compound is an approved medicine. Both are prohibited in sport. WADA lists BPC-157 under S0 "Non-approved substances" and thymosin beta-4 and its derivatives, including TB-500, under S2 "Peptide hormones, growth factors, related substances and mimetics". Both categories apply at all times. Details are available in the official WADA Prohibited List.
Both peptides are supplied as lyophilised powder and must be reconstituted before use in the lab. Our guide on how to reconstitute peptides explains the process step by step.
Frequently asked questions about BPC-157 vs TB-500
Is TB-500 the same as thymosin beta-4?
Which peptide has more research, BPC-157 or TB-500?
Can BPC-157 and TB-500 be mixed in one vial?
Sources
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. doi:10.1152/japplphysiol.00945.2010
Goldstein AL, Hannappel E, Sosne G, Kleinman HK (2012). Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. doi:10.1517/14712598.2012.634793
Philp D, Nguyen M, Scheremeta B, et al. (2004). Thymosin β4 increases hair growth by activation of hair follicle stem cells. The FASEB Journal. doi:10.1096/fj.03-0244fje
Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. doi:10.1007/s00441-019-03016-8
This article summarises published research for information only. It is not medical advice. All products on this site are sold for laboratory research use only and are not intended for human or veterinary use.
